Multiple Sclerosis Clinical Trials 2024

What are the top hospitals conducting multiple sclerosis research?

When it comes to advancing treatment options for multiple sclerosis (MS), several hospitals across the United States are leading the way in groundbreaking clinical trials. In Cleveland, Ohio, the renowned Cleveland Clinic is actively involved in five ongoing MS trials and has an impressive track record of 26 completed trials since their first recorded endeavor in 2005. Meanwhile, in Oklahoma City, the Oklahoma Medical Research Foundation is making significant contributions with four active MS trials and a total of 11 completed studies since initiating their first trial in 2011.

In Chicago, Illinois, the University of Illinois at Chicago is also dedicated to pioneering new treatments for MS through its participation in four ongoing clinical trials. Their commitment dates back to 2003 when they conducted their initial trial on this complex neurological disorder.

Another prominent institution contributing to our understanding of MS is the National Institutes of Health Clinical Center located in Bethesda, Maryland. With four active clinical trials and a remarkable history involving 15 previous investigations dating all the way back to their first recorded trial on MS in 1992.

Lastly but not least important,the University of Texas Southwestern Medical Center situated Dallas takes pride into offering three current clinical tests while holding around thirteen former inquiries;theirs can be traced back only seventeen years ago where they initiated exploration into managing this condition from as early as year2004

These hospitals serve as beacons of hope for those affected by multiple sclerosis by pushing forward medical boundaries through innovative research initiatives. The collective efforts displayed by these institutions underscore our commitment towards finding better treatment options and ultimately improving quality of life for individuals living with this chronic autoimmune disease

Which are the best cities for multiple sclerosis clinical trials?

When it comes to multiple sclerosis clinical trials, several cities emerge as leading hubs for research and development. Philadelphia, Pennsylvania stands out with 17 active trials focusing on treatments like RPC-1063, Ocrelizumab, and BNT162b2. New york, New York follows closely behind with 15 ongoing studies exploring interventions such as Ocrelizumab and Bivalent + Continue IS (MTX). Additionally, Cleveland, Ohio hosts 11 active trials investigating treatments like RPC-1063 and Cohort B. These cities serve as centers of excellence in multiple sclerosis research, offering individuals affected by the condition access to innovative therapies that hold promise for improved outcomes.

Which are the top treatments for multiple sclerosis being explored in clinical trials?

Multiple sclerosis (MS) research is at the forefront of medical advancements, with several promising treatments currently under exploration in clinical trials. The leading contenders include:

• Ocrelizumab: Demonstrating its potential, ocrelizumab is involved in seven active trials and has been a part of 48 multiple sclerosis studies since it was first listed in 2008.

• HB-adMSCs: A newcomer on the scene, HB-adMSCs are being investigated in one ongoing trial for MS. This therapy shows great promise as it enters the world of clinical research.

• Phase 3; MYOBLOC: Another recent addition to the list, phase 3 MYOBLOC holds significant potential for treating multiple sclerosis. Currently engaged in one active trial, this treatment option warrants close attention from researchers and patients alike.

These cutting-edge therapies offer hope for individuals living with MS and highlight the continuous efforts made to find effective solutions against this complex neurological disorder.

What are the most recent clinical trials for multiple sclerosis?

Recent clinical trials offer promising prospects for individuals living with multiple sclerosis. One such trial focuses on Clemastine Fumarate, which has progressed to Phase 2 after successful results in Phase 1. Another study examines the effectiveness of PIPE-791 as a potential treatment option for multiple sclerosis patients following positive outcomes in its Phase 1 trial. Additionally, an ongoing Phase 2 trial is investigating a novel treatment arm specifically tailored for individuals with multiple sclerosis. These advancements bring hope and optimism to those affected by this debilitating condition, showcasing the dedication of researchers and medical professionals towards improving patient care and quality of life.

What multiple sclerosis clinical trials were recently completed?

In recent years, several clinical trials have concluded in their quest to advance the understanding and treatment options for multiple sclerosis (MS). Notable among them is a trial sponsored by the University of Utah which focused on MRI Brain and Cervical Spine, completed in June 2022. Additionally, Mapi Pharma Ltd.'s GA Depot trial finished in September 2019, followed closely by Columbia University's Aspirin 650mg Oral Capsule study which concluded in April of that same year. Other significant trials include Novartis Pharmaceuticals' Siponimod (February 2019), Biogen's Natalizumab (November 2018), Tisch Multiple Sclerosis Research Center of New york's Intrathecal MSC-NP injection (September 2018), and Johns Hopkins University's Tauroursodeoxycholic Acid research (June 2018). These collective efforts demonstrate ongoing dedication towards advancing treatments for individuals living with MS.